01
Cash & equivalents increased 121.9%
Cash & equivalents changed +121.9% from the comparable as-filed period.
$5.2M→$11.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTREVELATION BIOSCIENCES, INC.'s latest supported as-filed period reports net income of -$3.3M, 36.0% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +121.9% from the comparable as-filed period.
Net income changed -36.0% from the comparable as-filed period.
Operating income changed -48.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
REVB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-357120SEC ↗4Aug 18, 2026Period Aug 17, 20260001193125-26-355663SEC ↗4Aug 18, 2026Period Aug 17, 20260001193125-26-355662SEC ↗4Aug 18, 2026Period Aug 17, 20260001193125-26-355661SEC ↗4Aug 18, 2026Period Aug 17, 20260001193125-26-355659SEC ↗4Aug 18, 2026Period Aug 17, 20260001193125-26-355658SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-338097SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 18, 2026 | Rolke JamesChief Executive Officer | Grant Or AwardDirect | 208,076 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +45.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Stock-based compensation changed +45881.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-337967